Estrogen dementia therapeutics - MIGENIX/Wyeth

Drug Profile

Estrogen dementia therapeutics - MIGENIX/Wyeth

Latest Information Update: 13 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MIGENIX
  • Developer Wyeth
  • Class
  • Mechanism of Action Estrogen receptor modulators; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 21 Sep 2004 Micrologix Biotech is now called MIGENIX
  • 06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech
  • 27 Jun 2001 Phase-III clinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top